Summary & Overview
HCPCS Level II J1096: Dexamethasone Lacrimal Ophthalmic Insert, 0.1 mg
HCPCS Level II code J1096 designates a lacrimal ophthalmic insert delivering dexamethasone 0.1 mg, a topical corticosteroid formulation for sustained ocular administration. This product-level drug code matters nationally as it identifies a specific ophthalmic therapeutic option used in eye care for controlling inflammation, ensuring billing clarity for clinics and pharmacies that dispense or place ophthalmic inserts.
Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, payer coverage considerations, and the clinical and billing context for use in ambulatory ophthalmology settings. The publication outlines common modifiers and coding practice elements, summarizes typical sites of service, and highlights where data is not available in the input.
Intended for coding professionals, billing managers, and eye care clinicians, the report provides benchmarks, policy updates, and clinical context related to HCPCS Level II code J1096. It clarifies which stakeholders are typically involved in coverage decisions and what information to expect when submitting claims for a lacrimal dexamethasone insert.
Billing Code Overview
HCPCS Level II code J1096 represents Dexamethasone, lacrimal ophthalmic insert, 0.1 mg. This code covers a topical ophthalmic drug delivered as a lacrimal insert intended for sustained administration to the eye.
Service type: Ophthalmic topical drug administration via lacrimal insert
Typical site of service: Eye care settings such as ophthalmology clinics, outpatient surgical centers, and other ambulatory eye care facilities
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with a history of chronic dry eye and recent cataract surgery presents to the ophthalmology clinic with localized postoperative inflammation and corneal epithelial disruption. The ophthalmologist determines that a sustained-release topical steroid is appropriate to control inflammation while minimizing systemic exposure and adherence issues. A dexamethasone lacrimal ophthalmic insert (J1096, dexamethasone, lacrimal ophthalmic insert, 0.1 mg) is placed into the inferior lacrimal punctum in the procedure room. The workflow includes informed consent, sterile placement of the insert, brief observation for immediate adverse effects, patient education on symptoms to report, and documentation of device lot number and insertion site. Follow-up is arranged within 1–2 weeks to assess inflammation control and to remove or confirm dissolution of the insert as clinically indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Routine reporting when no modifier applies |
22 | Increased procedural services |